C&R RESEARCH INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,720 KRW | -0.75% |
|
+0.17% | +44.54% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 48.5B 35.6M | Sales 2023 | 55.1B 40.44M | Capitalization | 65.27B 47.91M |
|---|---|---|---|---|---|
| Net income 2022 | 3.93B 2.88M | Net income 2023 | 5.56B 4.08M | EV / Sales 2022 | 1.22 x |
| Net cash position 2022 | 2.9B 2.13M | Net cash position 2023 | 5.41B 3.97M | EV / Sales 2023 | 1.09 x |
| P/E ratio 2022 |
15.6
x | P/E ratio 2023 |
12
x | Employees | 483 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 35.5% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.75% | ||
| 1 week | +0.17% | ||
| Current month | -8.51% | ||
| 1 month | -14.43% | ||
| 3 months | +32.72% | ||
| 6 months | +43.69% | ||
| Current year | +44.54% |
1 week
1 665.00
1 779.00
1 month
1 665.002 395.00
Current year
1 177.002 395.00
1 year
1 078.002 395.00
3 years
1 078.002 680.00
5 years
1 078.002 680.00
10 years
1 078.002 680.00
| Managers | Title | Age | Since |
|---|---|---|---|
Moon-Tae Yoon
CEO | Chief Executive Officer | 72 | 21-12-07 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Moon-Tae Yoon
CEO | Chief Executive Officer | 72 | 21-12-07 |
Hong-In No
BRD | Director/Board Member | 64 | - |
Jung-Hee Park
BRD | Director/Board Member | 60 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-20 | 1,720 | -0.75% | 720,053 |
| 24-05-17 | 1,733 | +0.99% | 1,576,460 |
| 24-05-16 | 1,716 | +1.42% | 728,994 |
| 24-05-14 | 1,692 | -1.46% | 984,386 |
End-of-day quote Korea S.E., May 19, 2024
More quotes
C&R Research Inc is a Korea-based company is mainly engaged in the clinical trial agency and drug development business. The Company is mainly engaged in the provision of comprehensive early-stage clinical services in the areas of medical writing, regulatory matters, data management, biostatistics and others. The Company is mainly engaged in the provision of consulting services including initial clinical development, clinical trial development, global clinical trial development and others. In addition, the Company is also engaged in the operation of clinical trial training center.
Calendar
2024-08-11
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +44.54% | 71.3M | |
| +41.79% | 54.04B | |
| +47.13% | 41.96B | |
| -0.56% | 41.92B | |
| -7.20% | 28.35B | |
| +12.59% | 26.35B | |
| -21.51% | 19B | |
| +6.92% | 13B | |
| +29.60% | 12.28B | |
| +24.91% | 12.19B |
- Stock Market
- Equities
- A359090 Stock